ReviewJournal of the Endocrine Society2026
Potential risk of neoplasms with fezolinetant: clinical evidence, mechanisms, and post-marketing implications.
Emma Boretti et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
1 paper cites it
this papercites it